跳至主要内容
临床试验/NCT02486276
NCT02486276已完成不适用

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model

Danish Headache Center1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Difference in median headache score 2 hours after sumatriptan/placebo

研究概览

简要总结

To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with a phosphodiesterase inhibitor (cilostazol). If the headache responds to sumatriptan, the model can be used to test new drug candidates.

详细描述

There remains a great need for more effective anti-migraine drugs with fewer side effects. Human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. The investigators' group has shown that Cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers and in patients with migraine without aura (MO). To validate this model, the headache must respond to specific migraine treatment with sumatriptan.

Hypothesis

Cilostazol induces a migraine-like headache in both healthy subjects and in MO-patients and induced headache responds to a specific anti migraine drug; sumatriptan.

Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Any type of headache (except episodic tension-type headache < 1 day per week)
  • Serious somatic or psychiatric disease
  • Pregnancy
  • Intake of daily medication (except oral contraceptives).
  • Migraine patients:
  • Any other type of headache then migraine without aura (except episodic tension-type headache < 1 day per week)
  • Serious somatic or psychiatric disease
  • Pregnancy
  • Intake of daily medication (except oral contraceptives)

研究组 & 干预措施

Sumatriptan

Active Comparator

headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg

干预措施: Cilostazol (Drug)

Sumatriptan

Active Comparator

headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg

干预措施: Sumatriptan (Drug)

Placebo

Placebo Comparator

headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo

干预措施: Cilostazol (Drug)

Placebo

Placebo Comparator

headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Difference in median headache score 2 hours after sumatriptan/placebo

时间窗: 2 hours

The investigators will assess the outcome measures 1 year after the beginning of the study

次要结局

  • Area under the headache score curve(12 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Emma Katrine Hansen

Medical doctor

Danish Headache Center

研究点 (1)

Loading locations...

相似试验